T. Hinks (Oxford, United Kingdom), C. Rolland-Debord (clermont-ferrand, France)
Associates of neutrophil/lymphocyte ratio in patients with COVID 19 infection: A single center experience B. Turan (Istanbul, Turkey), E. Baysal (Istanbul, Turkey), C. Ömür (Istanbul, Turkey), Y. Abdurrahman (Istanbul, Turkey), C. Çinar (Istanbul, Turkey), D. Kocakaya (Istanbul, Turkey), S. Olgun Yildizeli (Istanbul, Turkey), E. Eryüksel (Istanbul, Turkey), S. Karakurt (Istanbul, Turkey), B. Balcan (Istanbul, Turkey)
|   |
Biomarker profiles associated with COVID-19 severity and mortality S. Sánchez-Díez (Barcelona, Spain), C. Gómez Ollés (Barcelona, Spain), M. De Homdedeu (Barcelona, Spain), D. Espejo (Barcelona, Spain), C. Fábregas (Barcelona, Spain), M. Cruz (Barcelona, Spain), X. Muñoz (Barcelona, Spain)
|   |
Vitamin d3 and its association with covid-19 disease severity: a prospective study A. Mohanty (Jodhpur, India), G. Purohit (Jodhpur, India), C. Choudhary (Jodhpur, India), A. Kuwal (Jodhpur, India), V. Bajiya (Jodhpur, India)
|  |
RELATION BETWEEN FERRITIN LEVELS AND PULMONARY AFFECTATION IN COVID-19. E. Guzmán Ansado (Madrid, Spain), A. Ochoa-Ruiz (Madrid, Spain), N. Villamagua- Arias (Madrid, Spain), J. De Mesa Álvarez (Madrid, Spain), Á. Hidalgo Herranz (Madrid, Spain), S. Sans Pérez (Madrid, Spain), S. Torres Tienza (Madrid, Spain), C. Lorenzo Martinez (Madrid, Spain), M. Yanlli Bonduke (Madrid, Spain), J. Rodríguez-Fernández (Madrid, Spain), S. Campos Téllez (Madrid, Spain)
|   |
Can IL-6 serve as a reliable biomarker of clinical outcome in COVID19 pneumonia? G. Hardavella (Athens, Greece), I. Marinou (Athens, Greece), E. Keramida (Athens, Greece), E. Bellou (Athens, Greece), S. Mavrea (Athens, Greece), E. Georgakopoulou (Athens, Greece), I. Bracka (Athens, Greece), T. Daskalos (Athens, Greece), S. Mazarakis (Athens, Greece), I. Karampinis (Athens, Greece), M. Salomidou (Athens, Greece), A. Xipolitos (Athens, Greece), N. Anastasiou (Athens, Greece), D. Zorpidou (Athens, Greece), P. Demertzis (Athens, Greece), S. Karabela (Athens, Greece)
|   |
Thyroid dysfunction reflects severity of COVID-19 pneumonia in hospitalized patients I. Machairas - Sallas (Athe , Greece), L. Kolilekas (At , Greece), A. Levounets (At , Greece), D. Tsoukalas (Ath , Greece), E. Zervas (Athens, Greece), M. Gaga (Athens, Greece)
|  |
Neutrophil-to-lymphocyte : a useful biomarker for predicting severity in coronavirus disease-2019 (COVID19) W. Jelassi (Nabeul, Tunisia), N. Abid (Nabeul, Tunisia), M. Loukil (Nabeul, Tunisia), N. Gader (Nabeul, Tunisia), M. Ben Ali (Nabeul, Tunisia), I. Chaabane (Nabeul, Tunisia), K. Bouzaidi (Nabeul, Tunisia), H. Ghrairi (Nabeul, Tunisia)
|   |
Lactate dehydrogenase level: A predictive marker for severe COVID-19 infection W. Jelassi (Nabeul, Tunisia), N. Abid (Nabeul, Tunisia), M. Loukil Ben Ali (Nabeul, Tunisia), N. Gader (Nabeul, Tunisia), M. Ben Ali (Nabeul, Tunisia), I. Chaabane (Nabeul, Tunisia), K. Bouzaidi (Nabeul, Tunisia), H. Ghrairi (Nabeul, Tunisia)
|   |
Is serum 25-hydroxyvitamin D levels associated with severity of COVID-19 disease? A retrospective study M. Hunziker (Basel, Switzerland), K. Abig (Liestal, Switzerland), M. Bösing (Liestal, Switzerland), S. Giezendanner (Basel, Switzerland), F. Jaun (Liestal, Switzerland), G. Lüthi-Corridori (Liestal, Switzerland), A. Makhdoomi (Liestal, Switzerland), J. Muser (Liestal, Switzerland), J. Leuppi (Liestal, Switzerland)
|   |
Laboratory markers as predictor factor of clinical and radiological severity in hospitalized patient with covid-19 S. Majdoub Fehri (Gabes, Tunisia), I. Ketata (Gabes, Tunisia), R. Sellami (Gabes, Tunisia), W. Medi (Gabes, Tunisia), H. Kwass (Gabes, Tunisia)
|   |
COVID-19 Severity Index (SI): is it a sensitive predictor score for disease outcome in hospitalized patients? K. Gashynova (Dnipro, Ukraine), V. Rudakova (Dnipro, Ukraine), V. Rodionova (Dnipro, Ukraine), N. But (Dnipro, Ukraine)
|   |
Plasminogen activator inhibitor-1 (PAI-1) like the best mortality predictor of in the COVID-19-associated pneumonia K. Bielosludtseva (Dniepropetrovsk, Ukraine), T. Pertseva (Dniepropetrovsk, Ukraine)
|   |
Evolution of IL-6 as possible marker of viral control in Covid-19 C. De Diego Ramos (Zaragoza, Spain), L. López (Zaragoza, Spain), L. Torralba (Zaragoza, Spain), A. Lasierra (Huesca, Spain), R. Lahoz (Zaragoza, Spain), C. Abadía (Zaragoza, Spain), P. Ruiz De Gopegui (Zaragoza, Spain), A. Cebollada (Zaragoza, Spain), J. Godino (Zaragoza, Spain), B. Jimeno (Zaragoza, Spain), S. Bello (Zaragoza, Spain)
|   |
Lactate dehydrogenase (LDH) reinforcement in predicting Covid-19 patient’s outcomes H. Eid (Beirut, Lebanon), A. El Kik (Beirut, Lebanon), A. Riachy (Beirut, Lebanon), E. Mekhael (Beirut, Lebanon), K. Hoyek (Beirut, Lebanon), N. Nassim (Beirut, Lebanon), G. Khayat (Beirut, Lebanon), G. Sleilaty (Beirut, Lebanon), M. Riachy (Beirut, Lebanon)
|   |
Relationship between hypercoagulability of hospitalized patients with COVID-19 disease with the clinical course of the disease as determined by the method of rotational thromboelastometry(ROTEM). N. Loutsidi (Athens, Greece), M. Politou (Athens, Greece), V. Vlahakos (Athens, Greece), D. Korakakis (Athens, Greece), T. Kassi (Athens, Greece), A. Nika (Athens, Greece), A. Pouliakis (Athens, Greece), K. Eleuftheriou (Athens, Greece), A. Pappas (Athens, Greece), I. Kalomenidis (Athens, Greece)
|   |
THE MOST INFORMATIVE BIOMARKERS AS PREDICTORS OF MORTALITY IN COVID-19 PNEUMONIA Y. Huba (Dnipro, Ukraine), K. Bielosludtseva (Dnipro, Ukraine), L. Konopkina (Dnipro, Ukraine)
|   |
Prognostic value of initial KL-6 (Krebs von den Lungen 6) plasma level during COVID-19 pneumonia A. Letellier (Paris, France), C. Rolland-Debord (Paris, France), D. Luque Paz (Paris, France), G. Lefèvre (Paris, France), L. Pieroni (Paris, France), A. Parrot (Paris, France), J. Cadranel (Paris, France)
|   |
Poor nutritional status and dynapenia are highly prevalent in post-acute COVID-19 L. Capitelli (naples, Italy), F. De Blasio (naples, Italy), L. Scalfi (naples, Italy), B. Castellucci (naples, Italy), A. Sacco (naples, Italy), G. Miracco Berlingieri (naples, Italy), P. Alicante (naples, Italy), C. Candia (naples, Italy), V. Giacon (naples, Italy), F. Tafuro (naples, Italy), R. Mottola (naples, Italy), A. Sanduzzi Zamparelli (naples, Italy), M. Bocchino (naples, Italy)
|   |
Prognostic value of Platelet-to-lymphocyte ratio in hospitalized patients with COVID-19 pneumonia N. Boubaker (Tunis, Tunisia), I. Mejri (Tunis, Tunisia), N. Guediri (Tunis, Tunisia), S. Daboussi (Tunis, Tunisia), S. M'Hamdi (Tunis, Tunisia), C. Aichaouia (Tunis, Tunisia), K. Ayed (Tunis, Tunisia), Z. Moetemri (Tunis, Tunisia)
|   |
Adipokines levels in hospitalized patients for COVID-19 and their role in prognosis D. Rama Esendagli (Ankara, Turkey), D. Topcu (Ankara, Turkey), E. Gul (Ankara, Turkey), C. Alperen (Ankara, Turkey), S. Akcay (Ankara, Turkey)
|   |